Loading...

HEXO

BST:74H
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
74H
BST
CA$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
74H Share Price and Events
7 Day Returns
0%
BST:74H
0.4%
DE Pharmaceuticals
0%
DE Market
1 Year Returns
-
BST:74H
-25.4%
DE Pharmaceuticals
-14%
DE Market
74H Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
HEXO (74H) 0% 0% - - - -
DE Pharmaceuticals 0.4% -3.3% -9.3% -25.4% -29.4% 18.6%
DE Market 0% -1.9% -7.7% -14% -1.9% 10.7%
1 Year Return vs Industry and Market
  • No trading data on 74H.
  • No trading data on 74H.
Price Volatility
Industry
5yr Volatility vs Market

74H Value

 Is HEXO undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of HEXO to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for HEXO.

BST:74H Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:74H
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.6
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.595 (1 + (1- 26.5%) (0%))
0.595
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.8 * 9.46%)
8.11%

Discounted Cash Flow Calculation for BST:74H using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for HEXO is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:74H DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (CAD, Millions) -7.80 54.18 63.93 74.80 86.77
Source Analyst x1 Analyst x1 Est @ 18%, capped from 44.3% Est @ 17%, capped from 44.3% Est @ 16%, capped from 44.3%
Present Value
Discounted (@ 8.11%)
-7.21 46.36 50.60 54.76 58.76
Present value of next 5 years cash flows CA$203.27
BST:74H DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= CA$86.77 × (1 + 0.54%) ÷ (8.11% – 0.54%)
CA$1,153.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= CA$1,153.00 ÷ (1 + 8.11%)5
CA$780.79
BST:74H Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= CA$203.27 + CA$780.79
CA$984.06
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$984.06 / 198.14
CA$4.26
BST:74H Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:74H represents 0.8586x of TSX:HEXO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8586x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 4.97 x 0.8586
€4.26
Value per share (EUR) From above. €4.26
Current discount Discount to share price of €5.04
= -1 x (€5.04 - €4.26) / €4.26
-18.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of HEXO is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for HEXO's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are HEXO's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:74H PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-07-31) in CAD CA$-0.17
TSX:HEXO Share Price ** TSX (2018-09-07) in CAD CA$5.87
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 11.63x
Germany Market PE Ratio Median Figure of 413 Publicly-Listed Companies 17.56x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of HEXO.

BST:74H PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:HEXO Share Price ÷ EPS (both in CAD)

= 5.87 ÷ -0.17

-33.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HEXO is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • HEXO is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does HEXO's expected growth come at a high price?
Raw Data
BST:74H PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -33.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
85.8%per year
Germany Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 1.45x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.32x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for HEXO, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on HEXO's assets?
Raw Data
BST:74H PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-07-31) in CAD CA$1.67
TSX:HEXO Share Price * TSX (2018-09-07) in CAD CA$5.87
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.02x
Germany Market PB Ratio Median Figure of 556 Publicly-Listed Companies 1.85x
BST:74H PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:HEXO Share Price ÷ Book Value per Share (both in CAD)

= 5.87 ÷ 1.67

3.52x

* Primary Listing of HEXO.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • HEXO is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess HEXO's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. HEXO has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

74H Future Performance

 How is HEXO expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
85.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is HEXO expected to grow at an attractive rate?
  • HEXO's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • HEXO's earnings growth is expected to exceed the Germany market average.
  • HEXO's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:74H Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:74H Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 85.8%
BST:74H Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 67.4%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 9.4%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:74H Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:74H Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-07-31 382 49 88 2
2020-07-31 242 72 62 5
2019-07-31 110 -9 9 6
BST:74H Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-07-31 5 -22 -23
2018-04-30 4 -13 -12
2018-01-31 4 -10 -22
2017-10-31 4 -6 -14
2017-07-31 4 -5 -12
2017-04-30 4 -4 -15
2017-01-31 4 -4 -3
2016-10-31 3 -3 -3
2016-07-31 2 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • HEXO's earnings are expected to grow significantly at over 20% yearly.
  • HEXO's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:74H Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from HEXO Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:74H Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-07-31 0.41 0.46 0.35 2.00
2020-07-31 0.27 0.33 0.19 3.00
2019-07-31 0.05 0.05 0.04 2.00
BST:74H Past Financials Data
Date (Data in CAD Millions) EPS *
2018-07-31 -0.17
2018-04-30 -0.11
2018-01-31 -0.28
2017-10-31 -0.21
2017-07-31 -0.21
2017-04-30 -0.30
2017-01-31 -0.06
2016-10-31 -0.07
2016-07-31 -0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if HEXO will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess HEXO's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
HEXO has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

74H Past Performance

  How has HEXO performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare HEXO's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • HEXO does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare HEXO's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare HEXO's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
HEXO's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from HEXO Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:74H Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-07-31 4.93 -23.35 22.71
2018-04-30 4.39 -11.91 14.42 0.09
2018-01-31 4.33 -21.74 11.73 0.09
2017-10-31 4.06 -13.91 8.17 0.13
2017-07-31 4.10 -12.42 7.34
2017-04-30 4.29 -14.72 6.56 0.02
2017-01-31 3.72 -3.32 5.19 0.03
2016-10-31 2.99 -2.88 4.19 0.09
2016-07-31 1.87 -3.35 3.53 0.11
2015-07-31 0.00 -2.71 2.42 0.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if HEXO has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if HEXO has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if HEXO improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess HEXO's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
HEXO has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

74H Health

 How is HEXO's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up HEXO's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • HEXO is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • HEXO has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of HEXO's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • HEXO has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from HEXO Company Filings, last reported 4 months ago.

BST:74H Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-07-31 322.87 0.00 251.67
2018-04-30 291.81 0.00 248.95
2018-01-31 288.46 0.00 264.66
2017-10-31 31.43 21.15 35.25
2017-07-31 32.44 20.64 41.32
2017-04-30 27.29 0.02 19.31
2017-01-31 21.35 3.02 17.12
2016-10-31 7.71 0.34 1.15
2016-07-31 7.79 0.31 1.93
2015-07-31 3.60 1.67 0.42
  • HEXO has no debt.
  • HEXO currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • HEXO has sufficient cash runway for more than 3 years based on current free cash flow.
  • HEXO has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 113% each year.
X
Financial health checks
We assess HEXO's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. HEXO has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

74H Dividends

 What is HEXO's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from HEXO dividends.
If you bought €2,000 of HEXO shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate HEXO's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate HEXO's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:74H Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 31 Stocks 3.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:74H Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2021-07-31
2020-07-31
2019-07-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as HEXO has not reported any payouts.
  • Unable to verify if HEXO's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of HEXO's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as HEXO has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess HEXO's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can HEXO afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. HEXO has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

74H Management

 What is the CEO of HEXO's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sebastien St-Louis
COMPENSATION CA$671,013
AGE 34
TENURE AS CEO 5.3 years
CEO Bio

Mr. Sebastien G. St-Louis is the Co-Founder of The Hydropothecary Corporation and has been its Chief Executive Officer, President and Director since August 13, 2013. Mr. St-Louis also founded Shield Real Estate Investments Inc. in 2012 and serves as its President. He served as a Senior Account Manager at the Business Development Bank of Canada from 2008 to 2011 and as Chief Financial officer of Wholesale Autoparts Warehouses from 2011 to 2012. Mr. St-Louis holds an MBA, DESS, finance from the Université du Québec à Montréal and a Bachelor of Arts from the University of Ottawa.

CEO Compensation
  • Sebastien's compensation has increased whilst company is loss making.
  • Sebastien's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the HEXO management team in years:

1.3
Average Tenure
48
Average Age
  • The average tenure for the HEXO management team is less than 2 years, this suggests a new team.
Management Team

Sebastien St-Louis

TITLE
Co-Founder
COMPENSATION
CA$671K
AGE
34
TENURE
5.3 yrs

Adam Miron

TITLE
Co-founder
COMPENSATION
CA$390K
AGE
34

Ed Chaplin

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$527K
AGE
48
TENURE
4.2 yrs

Jay McMillan

TITLE
Vice President of Business Development
COMPENSATION
CA$506K
AGE
50
TENURE
3.4 yrs

Jennifer Smith

TITLE
Manager of Financial Reporting & Investor Relations

Max Cyr

TITLE
Director of Customer Experience & Compliance

Roch Vaillancourt

TITLE
General Counsel
TENURE
0.8 yrs

Pierre Killeen

TITLE
Vice-President of Corporate Communications & Government Relations
TENURE
1.3 yrs

Sonia Isabel

TITLE
Vice-President of Sales
TENURE
0.8 yrs

Nick Davies

TITLE
Chief Marketing Officer
AGE
55
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the HEXO board of directors in years:

4.1
Average Tenure
45
Average Age
  • The tenure for the HEXO board of directors is about average.
Board of Directors

Michael Munzar

TITLE
Chairman
COMPENSATION
CA$160K
AGE
64

Sebastien St-Louis

TITLE
Co-Founder
COMPENSATION
CA$671K
AGE
34
TENURE
5.3 yrs

Adam Miron

TITLE
Co-founder
COMPENSATION
CA$390K
AGE
34
TENURE
5.3 yrs

Jason Ewart

TITLE
Director
COMPENSATION
CA$86K
AGE
45
TENURE
4.1 yrs

Vincent Chiara

TITLE
Director
COMPENSATION
CA$67K
AGE
56
TENURE
2.1 yrs

Nathalie Bourque

TITLE
Director
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • HEXO insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Nov 18 Sell Jason Ewart Individual 22. Nov 18 22. Nov 18 -15,000 €3.84 €-57,535
07. Nov 18 Sell Ed Chaplin Individual 02. Nov 18 02. Nov 18 -35,000 €4.19 €-146,528
02. Oct 18 Buy Vincent Chiara Individual 28. Sep 18 28. Sep 18 6,700 €5.85 €39,213
25. Sep 18 Sell Michael Munzar Individual 20. Sep 18 20. Sep 18 -126,000 €5.41 €-681,401
14. Sep 18 Sell Michael Munzar Individual 12. Sep 18 12. Sep 18 -10,000 €5.84 €-58,381
13. Sep 18 Sell Terence Lake Individual 07. Sep 18 07. Sep 18 -1,500 €5.02 €-7,529
13. Sep 18 Sell Michael Munzar Individual 07. Sep 18 07. Sep 18 -162,000 €5.08 €-823,331
27. Aug 18 Sell Jason Ewart Individual 21. Aug 18 21. Aug 18 -15,000 €3.25 €-48,761
20. Aug 18 Sell Ed Chaplin Individual 15. Aug 18 15. Aug 18 -30,000 €3.03 €-90,724
30. Apr 18 Sell Ed Chaplin Individual 26. Apr 18 30. Apr 18 -30,000 €2.76 €-82,255
17. Apr 18 Sell Michael Munzar Individual 12. Apr 18 12. Apr 18 -250,000 €2.59 €-648,648
08. Dec 17 Buy Terence Lake Individual 30. Nov 17 30. Nov 17 2,000 €1.62 €3,222
13. Mar 18 Buy Vincent Chiara Individual 27. Dec 17 27. Dec 17 625,000 €1.06 €664,586
09. Mar 18 Sell Sebastien St-Louis Individual 05. Mar 18 05. Mar 18 -156,000 €2.38 €-370,929
06. Mar 18 Sell Sebastien St-Louis Individual 02. Mar 18 02. Mar 18 -84,000 €2.30 €-193,441
X
Management checks
We assess HEXO's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. HEXO has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

74H News

External News
Loading...
Simply Wall St News

74H Company Info

Map
Description

HEXO Corp., through its subsidiary, HEXO Operations Inc., produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names. The company serves medical and adult-use markets. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. is headquartered in Gatineau, Canada.

Details
Name: HEXO Corp.
74H
Exchange: BST
Founded:
CA$776,892,154
198,136,684
Website: http://hexo.com
Address: HEXO Corp.
240 – 490 Boulevard Sainte-Joseph,
Gatineau,
Quebec, J8Y 3W9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX HEXO Common Shares The Toronto Stock Exchange CA CAD 21. Mar 2017
OTCPK HYYD.F Common Shares Pink Sheets LLC US USD 21. Mar 2017
DB 74H Common Shares Deutsche Boerse AG DE EUR 21. Mar 2017
BST 74H Common Shares Boerse-Stuttgart DE EUR 21. Mar 2017
Number of employees
Current staff
Staff numbers
220
HEXO employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/12/04 19:53
End of day share price update: 2018/09/07 00:00
Last estimates confirmation: 2018/11/08
Last earnings filing: 2018/10/26
Last earnings reported: 2018/07/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.